Wall Street analysts have painted a tantalizing picture of triple-digit upside potential for some of this year’s worst-performing biotech names. Yet investors may want to temper their excitement. While innovative in their fields, gene-editing specialist Intellia Therapeutics (NTLA) and cell therapy company Iovance Biotherapeutics (IOVA) each face significant challenges, with their shares down 19% and 61% year to date, respectively.
According to data from Yahoo! Finance, however, the average analyst price targets suggest eye-popping potential gains of 139% for Intellia and 191% for Iovance. The critical question for investors: Is this a genuine opportunity or a value trap?
Intellia Therapeutics, a pioneer in CRISPR-based gene editing, recently hit a major clinical roadblock. Its lead candidate, nex-z, developed for the treatment of transthyretin amyloidosis (ATTR)—a rare, progressive disease that can cause severe cardiovascular complications—was placed on clinical hold by U.S. regulators. The hold followed the death of a trial participant due to liver injury during a pair of Phase 3 studies.
The stock plunged in response. Although it remains unclear whether nex-z was responsible for the patient’s death, the uncertainty has left the company in a holding pattern until the U.S. Food and Drug Administration (FDA) provides further clarity. Should the therapy be cleared of responsibility, a sharp rebound in the stock is possible.
Yet even in a best-case scenario, nex-z must still clear significant clinical and regulatory hurdles before generating revenue. Moreover, gene-editing therapies are notoriously complex and costly to manufacture and administer. For a biotech of Intellia’s size, securing payer coverage and building a specialized treatment network pose additional challenges—issues that also apply to its other late-stage gene-editing therapy, lonvo-z.
As a result, the stock remains highly speculative, even if nex-z is exonerated.
Iovance, on the other hand, already has an approved product on the market. Amtagvi, a personalized cell therapy for advanced melanoma that leverages a patient’s own tumor-derived cells, has seen solid commercial uptake since its launch last year. In the first nine months of 2025, the company reported revenue of $176.7 million—almost entirely from Amtagvi—nearly double the figure from the same period a year earlier.
The company has made commercial progress, gaining approval in Canada and pursuing regulatory submissions in Europe and Australia. Amtagvi is also being tested in additional clinical trials, which could support future label expansions. Iovance estimates the therapy currently addresses about 30,000 patients globally—a number that could grow meaningfully with new indications.
Despite these positives, the stock continues to trend downward. A key reason is the therapy’s complex and costly logistics: Amtagvi requires tumor extraction, customized manufacturing at a specialized facility, chemotherapy conditioning, and reinfusion—a process spanning weeks and carrying a high price tag. This has made a clear path to profitability elusive for Iovance, weighing heavily on investor sentiment. Given these operational and financial headwinds, a near-term surge in the stock—let alone a 191% rally—appears unlikely.
While Wall Street’s optimistic targets reflect recognition of both companies’ innovative technologies, investors should remain acutely aware of the substantial uncertainties ahead. Intellia’s clinical setbacks and Iovance’s profitability challenges represent significant barriers that won’t be easily overcome.
For most investors, watching from the sidelines—until clearer clinical and commercial progress emerges—may be the prudent approach. In biotech, high potential upside often comes with equally high risk.
